Ferring Pharmaceuticals ( Ferring Pharmaceuticals)

Primary tabs

Ferring Pharmaceuticals's picture

Management

Contact Address

About Ferring Pharmaceuticals

Ferring Pharmaceuticals Inc. is a subsidiary of Ferring Pharmaceuticals, a privately owned, international pharmaceutical company. Ferring Pharmaceuticals specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, gastroenterology, infertility, obstetrics/gynecology, orthopaedics, and urology.

Ferring Pharmaceuticals press release, blog etc

Mon, 01/27/2025 - 11:45 Ferring Highlights Commitment to C. Diff Infection Community on the Second Anniversary of the Launch of REBYOTA (fecal microbiota, live jslm)
Mon, 06/24/2024 - 12:48 Ferring to Present New Data Analyses at ASPN 2024 for SI-6603, an Investigational Treatment for Lumbar Disc Herniation
Thu, 06/20/2024 - 13:49 Ferring Pharmaceuticals and Posterity Health Launch New Partnership to Activate Men About Their Fertility
Tue, 05/14/2024 - 14:35 Ferring Announces U.S. FDA Acceptance of Biologics License Application Submission for SI-6603, an Investigational Therapy in Lumbar Disc Herniation
Thu, 12/15/2022 - 21:24 Ferring Receives Approval from U.S. FDA for Adstiladrin for High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Tue, 11/29/2022 - 22:44 Ferring Receives U.S. FDA Approval for REBYOTA (fecal microbiota, live-jslm) A Novel First-in-Class Microbiota-Based Live Biotherapeutic
Mon, 11/28/2022 - 06:31 Ferring Appreciates Ongoing Support from New Jersey and Minnesota as Both States Issue Proclamations Recognizing November as C. Difficile Infection Awareness Month
Mon, 11/07/2022 - 00:06 Pivotal Phase 3 Efficacy and Safety Data for Ferrings RBX2660 Published in Drugs
Fri, 10/21/2022 - 11:47 Ferring Pharmaceuticals Announces the Launch of FertilityWise a New, On-Demand E-Learning Program for Fertility Clinic Staff
Thu, 10/20/2022 - 11:08 Ferring Presents New Subgroup Analyses of Health-Related Quality of Life and Safety and Efficacy Data at IDWeek 2022 for RBX2660
Wed, 10/19/2022 - 10:35 Ferring Pharmaceuticals to Present New Data Highlighting Future Assisted Reproductive Technology Market Trends at ASRM 2022 Scientific Congress & Expo
Tue, 10/18/2022 - 05:11 Ferring Introduces Fertility Outreach, a Text-based Platform Providing Aspiring Parents with Access to a Live Fertility Coach
Thu, 10/06/2022 - 06:22 Ferring to Present Analyses for Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Patients with Recurrent C. Difficile Infection at IDWeek 2022
Thu, 09/22/2022 - 15:13 Ferring Receives Positive Vote from U.S. FDA Advisory Committee for RBX2660
Thu, 09/22/2022 - 14:20 Ferring Announces U.S. FDA Advisory Committee Meeting for RBX2660 its Investigational Microbiota-based Live Biotherapeutic
Thu, 09/15/2022 - 11:30 Partnering to Help Drive Reproductive Medicine and Maternal Health Forward
Wed, 05/11/2022 - 11:39 Ferring to Present Analyses for Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Patients with Recurrent C. Difficile Infection at DDW 2022
Tue, 02/15/2022 - 09:13 Ferring Announces Investment in Robyn, an Online Community that Provides Access to Fertility and Parental Wellness Resources